|
| Status |
Public on May 03, 2012 |
| Title |
Trastuzumab and Pertuzumab treated after 4 days (TP1_2) |
| Sample type |
RNA |
| |
|
| Source name |
Ovarian Cancer xenograft
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: SCOV3
|
| Treatment protocol |
The mice were treated with trastuzumab (20 mg/kg), pertuzumab (20 mg/kg) and trastuzumab + pertuzumab (20 mg/kg each)
|
| Growth protocol |
Adult female nu/nu mice were implanted subcutaneously with SKOV3 tumor fragments (previously established from the cell line) or primary ovarian tumor fragments in the flanks and allowed to grow to 4–6 mm in diameter (over a period of approximately 1 month).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was prepared from 10-50 mg of frozen tissue after 4 days of treatment, preincubated with RNAlater-ICE (Ambion, Austin, TX) using the miRNeasy Mini kit (Qiagen) and TissueRuptor (Qiagen) following the manufacturers’ instructions
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays
|
| |
|
| Hybridization protocol |
Standard Illumina hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Description |
replicate 2
TP1_2
|
| Data processing |
The data were normalised using quantile normalisation with the BioConductor package, Lumi in R
|
| |
|
| Submission date |
Aug 17, 2011 |
| Last update date |
May 03, 2012 |
| Contact name |
Andrew H Sims |
| E-mail(s) |
[email protected]
|
| Organization name |
University of Edinburgh
|
| Department |
Institute of Genetics and Molecular Medicine
|
| Lab |
Applied Bioinformatics of Cancer
|
| Street address |
Systems Medicine Building
|
| City |
Carrington Crescent |
| State/province |
Edinburgh |
| ZIP/Postal code |
EH4 2XR |
| Country |
United Kingdom |
| |
|
| Platform ID |
GPL6947 |
| Series (1) |
| GSE31432 |
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer |
|
